Can Lupin use oseltamivir approval to deepen its China respiratory medicine strategy?
Lupin’s China approval adds a paediatric-friendly flu antiviral to its portfolio. See why formulation and access still matter in generics.
Lupin just cracked China with a flu drug. Why investors may want to look closer
Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.
Can Lupin Limited gain ground in cardiometabolic generics with United States dapagliflozin launch?
Lupin Limited has launched generic dapagliflozin in the United States. Read what it means for Farxiga, pricing pressure, and market access.
Lupin closes VISUfarma deal, but can branded ophthalmology drive the next phase of growth?
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.
Lupin Limited moves closer to the Wakix market as pitolisant tentative approval sharpens future optionality
Lupin Limited has won tentative FDA approval for pitolisant tablets. Read why timing, exclusivity, and Wakix market dynamics matter next.